Literature DB >> 17323996

Semisynthetic approaches to laspartomycin analogues.

William V Curran1, Richard A Leese, Howard Jarolmen, Donald B Borders, Dominique Dugourd, Yuchen Chen, Dale R Cameron.   

Abstract

Laspartomycin C (1), a lipopeptide antibiotic related to amphomycin, consists of a cyclic peptide core and an aspartic acid unit external to the core and linking this to a C15-2,3-unsaturated fatty acid. This was reported initially to be active against Staphylococcus aureus, and more recent studies have shown that it is active against VRE, VISA, and MRSA isolates. The enzymatic cleavage of the fatty acid tail was accomplished with a deacylase produced by Actinoplanes utahensis and resulted in two peptides, designated Peptide 1 and Peptide 2. Semisynthetic derivatives of both peptides have been made, and the principal requirement for biological activity appears to be the presence of an acylaspartic acid.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17323996     DOI: 10.1021/np068062b

Source DB:  PubMed          Journal:  J Nat Prod        ISSN: 0163-3864            Impact factor:   4.050


  4 in total

Review 1.  Therapeutic cyclic lipopeptides mining from microbes: latest strides and hurdles.

Authors:  Seema Patel; Shadab Ahmed; J Satya Eswari
Journal:  World J Microbiol Biotechnol       Date:  2015-06-04       Impact factor: 3.312

Review 2.  The calcium-dependent lipopeptide antibiotics: structure, mechanism, & medicinal chemistry.

Authors:  Thomas M Wood; Nathaniel I Martin
Journal:  Medchemcomm       Date:  2019-03-21       Impact factor: 3.597

3.  Molecular cloning and identification of the laspartomycin biosynthetic gene cluster from Streptomyces viridochromogenes.

Authors:  Yang Wang; Ying Chen; Qirong Shen; Xihou Yin
Journal:  Gene       Date:  2011-05-27       Impact factor: 3.688

4.  Deacylation of Calcium-Dependent Antibiotics from Streptomyces violaceoruber in Co-culture with Streptomyces sp. MG7-G1.

Authors:  Kathrin Schindl; Deepika Sharma; Dieter Spiteller
Journal:  Chembiochem       Date:  2020-07-20       Impact factor: 3.164

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.